润达医疗
(603108)
| 流通市值：90.07亿 | | | 总市值：90.07亿 |
| 流通股本：6.04亿 | | | 总股本：6.04亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 5,268,459,587.79 | 3,470,487,876.09 | 1,661,846,010.13 | 8,311,780,357.39 |
| 营业收入 | 5,268,459,587.79 | 3,470,487,876.09 | 1,661,846,010.13 | 8,311,780,357.39 |
| 二、营业总成本 | 5,307,471,760.12 | 3,514,567,613.8 | 1,695,369,724.19 | 7,994,783,190.57 |
| 营业成本 | 4,134,821,387.13 | 2,743,783,854.18 | 1,316,525,968.41 | 6,203,492,198.74 |
| 税金及附加 | 21,422,146.27 | 14,232,635.04 | 6,934,547.78 | 40,981,347.66 |
| 销售费用 | 562,371,124.47 | 369,623,684.99 | 178,199,424.07 | 840,777,045.98 |
| 管理费用 | 303,152,989.12 | 200,072,067.55 | 104,063,010.8 | 479,941,188.72 |
| 研发费用 | 82,554,832.89 | 55,211,793.34 | 25,747,739.45 | 116,156,442.1 |
| 财务费用 | 203,149,280.24 | 131,643,578.7 | 63,899,033.68 | 313,434,967.37 |
| 其中:利息费用 | 208,662,636.08 | 140,429,424.15 | 68,139,704.78 | 312,858,681.19 |
| 其中:利息收入 | 10,040,351.09 | 8,659,031.75 | 5,765,532.67 | 13,365,461.21 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 66,886,817.47 | 47,447,216.74 | 20,673,577.45 | 109,820,881.18 |
| 资产处置收益 | 893,530.01 | -958,792.77 | 645,775.8 | 11,463,482.16 |
| 资产减值损失(新) | -70,339.94 | -45,795.63 | -70,183.53 | -36,170,132.75 |
| 信用减值损失(新) | -110,956,271.25 | -73,969,820.68 | -44,888,893.6 | -81,714,124.65 |
| 其他收益 | 24,748,191.11 | 20,117,157.69 | 8,056,159.19 | 33,662,573.6 |
| 四、营业利润 | -57,510,244.93 | -51,489,772.36 | -49,107,278.75 | 354,059,846.36 |
| 加:营业外收入 | 3,069,154.88 | 1,798,808.11 | 908,322.37 | 622,456.3 |
| 减:营业外支出 | 7,346,697.45 | 3,369,511.22 | 527,290.34 | 9,140,103.78 |
| 五、利润总额 | -61,787,787.5 | -53,060,475.47 | -48,726,246.72 | 345,542,198.88 |
| 减:所得税费用 | 64,415,776.3 | 46,421,694.58 | 19,136,755.54 | 156,084,177.83 |
| 六、净利润 | -126,203,563.8 | -99,482,170.05 | -67,863,002.26 | 189,458,021.05 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -126,203,563.8 | -99,482,170.05 | -67,863,002.26 | 189,458,021.05 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -162,691,533.55 | -120,652,208.04 | -69,258,725.43 | 55,280,607.97 |
| 少数股东损益 | 36,487,969.75 | 21,170,037.99 | 1,395,723.17 | 134,177,413.08 |
| 扣除非经常损益后的净利润 | -178,282,052.02 | -134,139,032.15 | -75,937,855.91 | 31,456,499.3 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.27 | -0.2 | -0.11 | 0.09 |
| (二)稀释每股收益 | -0.27 | -0.2 | -0.11 | 0.09 |
| 八、其他综合收益 | -285,439.17 | -1,094,094.88 | 61,323.97 | 2,915,308.12 |
| 归属于母公司股东的其他综合收益 | -262,060.32 | -1,008,558.78 | 56,518.06 | 2,564,784.67 |
| 九、综合收益总额 | -126,489,002.97 | -100,576,264.93 | -67,801,678.29 | 192,373,329.17 |
| 归属于母公司股东的综合收益总额 | -162,953,593.87 | -121,660,766.82 | -69,202,207.37 | 57,845,392.64 |
| 归属于少数股东的综合收益总额 | 36,464,590.9 | 21,084,501.89 | 1,400,529.08 | 134,527,936.53 |
| 公告日期 | 2025-10-30 | 2025-08-27 | 2025-04-26 | 2025-04-26 |
| 审计意见(境内) | | | | 标准无保留意见 |